← Back to Clinical Trials
Recruiting NCT07307183

NCT07307183 Prediction Model for the Risk of Developing Foot Ulcers in Diabetes

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07307183
Status Recruiting
Phase
Sponsor Sahlgrenska University Hospital
Condition Diabete Mellitus
Study Type OBSERVATIONAL
Enrollment 100,000 participants
Start Date 2014-01-30
Primary Completion 2027-12-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100,000 participants in total. It began in 2014-01-30 with a primary completion date of 2027-12-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Introduction Foot ulcers in diabetes mellitus (DM) are a common and serious complication that can lead to infection, amputation, and increased mortality. Early identification of patients at high risk is crucial in order to implement preventive measures at an early stage. The number of people with DM is increasing globally, from 540 million in 2021 to an estimated 780 million by 2045. Foot ulcers cause considerable suffering for the individual and entail substantial costs for the healthcare system. Despite national guidelines recommending regular, structured foot examinations and risk classification to assess the risk of developing foot ulcers, current risk models do not take into account the complex interactions between risk factors and socioeconomic factors such as marital status, level of education, and place of residence. Data-driven advances and artificial intelligence (AI) offer new opportunities to refine risk identification, but their use in predicting the risk of diabetic foot ulcers remains limited. The need for foot screening is considerable. In Sweden, there are approximately 600,000 patients with DM, and half of them live with an increased risk due to nerve damage in the feet. This means that, based on risk level, around 300,000 patients in Sweden may require preventive interventions, including medical foot care, customised footwear, and access to specialist care for those with foot ulcers. Improved preventive efforts are emphasised in the person-centred and integrated care pathway for people with diabetes at high risk of foot ulcers. However, accurate identification of foot ulcer risk is currently lacking. Prevention leads not only to good quality of life for the individual but also to reduced healthcare costs. Estimates by Ragnarsson Tennvall show that a hard-to-heal ulcer costs approximately SEK 100,000 per year, while an amputation costs around SEK 300,000-500,000. Given a prevalence of foot ulcers of 5% among patients with diabetes, the annual cost of ulcer care amounts to SEK 3 billion. In addition, there are costs of approximately SEK 750 million for amputations, according to data from the quality register SwedAmp. The aim of the study is to develop, test, and validate prediction models (statistical and AI-based) to identify patients with DM who are at risk of developing foot ulcers. The models will be based on retrospective electronic health record data from primary care in the Västra Götaland Region (VGR), as well as data from Statistics Sweden (SCB) concerning demographic factors such as marital status, level of education, occupation, and place of residence. Methods The study has two methodological approaches: AI-based modelling and statistical modelling. AI-based approach Machine learning models will be developed to predict patients at risk of developing diabetic foot ulcers. The models will be trained using cross-validation on a large dataset in which variables will be iteratively excluded. Conformal prediction will be used to quantify uncertainty in patient-level predictions. The resulting models will be analysed to identify the strongest predictors and will be compared with classical statistical modelling and findings from the literature. Steps in AI modelling: Data extraction: Electronic health record data from primary care in VGR, supplemented with sociodemographic data from SCB. Data processing: Use of, among other variables, diagnostic codes (ICD-10), healthcare interventions (KVÅ codes), visit types, visit frequency, ECG parameters, and free-text data to construct predictors. Model development: Prediction models will be developed and trained using cross-validation. Measures of uncertainty will be generated using conformal prediction. Validation: A separate cohort will be used to test model performance (sensitivity, specificity, positive predictive value \[PPV\]). Interpretation: The models will be reviewed for transparency and clinical interpretability in collaboration with patient representatives, clinicians, and researchers. The results of the statistical and AI-based models will be compared with regard to their respective strengths and weaknesses. Statistical modelling Two populations will be analysed: patients with diabetes without foot ulcers and patients with diabetes with foot ulcers. Co-variation and causal relationships between risk factors and foot ulcers will be identified. A model describing causal pathways leading to ulcer development will be developed, and its certainty and uncertainty will be analysed.

Eligibility Criteria

Inclusion Criteria: * Adult patients aged 18 years or older at the time of inclusion * Patients with a diagnosis of diabetes mellitus according to ICD-10 codes E10-E14, and/or * Patients who have been prescribed at least one diabetes-related medication after the age of 18 * Patients with relevant diagnoses and/or prescriptions recorded in the study data sources between 1 January 2014 and 30 June 2025 Exclusion Criteria: * Patients younger than 18 years of age at the time of diabetes diagnosis or prescription * Patients with no recorded diagnosis of diabetes (ICD-10 E10-E14) and no prescription of diabetes medication after the age of 18 * Patients with incomplete or missing key data required for model development or validation (e.g. missing outcome or essential covariates)

Contact & Investigator

Central Contact

Ulla Hellstrand Tang, Associate Professor

✉ ulla.tang@vgregion.se

📞 +46706397913

Principal Investigator

Ulla Hellstrand Tang, Associate Professor

PRINCIPAL INVESTIGATOR

The Department of Prosthetics & Orthotics at the Department for Biomedical Engineering and Medical Physics at Sahlgrenska University Hospital, Gothenburg, Sweden

Frequently Asked Questions

Who can join the NCT07307183 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Diabete Mellitus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07307183 currently recruiting?

Yes, NCT07307183 is actively recruiting participants. Contact the research team at ulla.tang@vgregion.se for enrollment information.

Where is the NCT07307183 trial being conducted?

This trial is being conducted at Jonsered, Sweden.

Who is sponsoring the NCT07307183 clinical trial?

NCT07307183 is sponsored by Sahlgrenska University Hospital. The principal investigator is Ulla Hellstrand Tang, Associate Professor at The Department of Prosthetics & Orthotics at the Department for Biomedical Engineering and Medical Physics at Sahlgrenska University Hospital, Gothenburg, Sweden. The trial plans to enroll 100,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology